Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM-398 and Veliparib in Solid Tumors
NCT02631733Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- May 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of veliparib in solid tumor, sponsored by National Cancer Institute. Primary endpoints: Incidence of adverse events up to 4 weeks and Maximum tolerated dose and recommended phase II dose. Started May 2017; status: completed.
02
Drugs
veliparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02631733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02631733.